July 11, 2013
With Plandai’s Products, East Meets West
It is no secret that the origins of green tea and black tea are derived from nations in the Far East, such as China. The West was first introduced to tea in the 16th and 17th centuries when it took Britain by storm. This beverage, which was likely used as medicinal or therapeutic drink from the outset, was later introduced to India where it become a staple of industry as well as culture. Historically, the varied health benefits associated with tea have been deemed to be many. Until a recent landmark study by Plandai Biotechnology, Inc. (OTCQB – PLPL - $0.48 – Spec Buy) that demonstrated the greatest absorption of the key nutrients, known as catechins, found in green tea into the bloodstream, many of the studies conducted on green tea’s health benefits have come from the Far East. Interestingly, while the Asian studies have been profound for their findings, they serve as an important precursor to the upcoming and game-changing Plandai extended studies.
Much like green tea was introduced by the East to the West, early studies of green tea’s health benefits were largely conducted in Asia, with significant results. Some of these early human studies have even shown that drinking at least two cups of green tea daily inhibits cancer growth.
For example, a study conducted in Japan that involved nearly 500 Japanese women with Stage I and Stage II breast cancer, found that increased green tea consumption before and after surgery was associated with lower recurrence of the cancers. Likewise, studies in China have demonstrated that the more green tea that participants drank, the less the risk of developing multiple forms of cancer. Separately, a study that involved 500 Japanese men and women found that drinking at least four cups of green tea every day may be related to the reduced severity of coronary heart disease among men.
Separately, a recent analysis of 22 studies that probed the correlation between high tea consumption and reduced risk for lung cancer concluded that by increasing the consumption of green tea by two cups each day may reduce the risk of developing lung cancer.
Clearly, the properties in the green tea catechins and antioxidants have a positive impact on our health. However, since there is limited bioavailability or absorption potential into the bloodstream, daily tea consumption in beverage form has had to be significant in order to receive its benefits. Conversely, Plandai has demonstrated that due to its extraction and delivery process, absorption rates of these key nutrients through its products can be many times that of typical bioavailability rates. Therefore, it is logical to assume that going forward, studies in the West will show even greater health benefits from these catechins than the studies conducted in the East. These results should then lead to increased and broader consumption of green tea and green tea extracts, led by Plandai’s offerings and ingredients in many manufacturers’ products across the globe.
For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.